Comments
Sun Pharma on Tuesday reported a consolidated net profit of ₹2,166 crore for the third quarter ended December 31, 2022.
The Mumbai-based company had posted a net profit of ₹2,059 crore for October-December period of the previous fiscal year.
Total revenue from operations stood at ₹11,241 crore in the period under review. It was ₹9,863 crore in the year-ago quarter, Sun Pharmaceutical Industries said in a regulatory filing.
Also read:Sun Pharma Q3 net zooms nearly four fold to ₹1,241.85 crore
On February 28, 2022, the company's subsidiary Taro Pharmaceutical Industries had acquired all of the outstanding capital stock of Galderma Holdings Inc; Proactiv YK ; The Proactiv Company Corporation and its other assets, the drug major said.
Accordingly, results for the quarter and nine months ended December 31, 2022 are not comparable to the year-ago periods', it noted.
The company's board, which met on Tuesday, also approved an interim dividend of ₹7.50 per share of ₹1 for 2022-23.
Shares of the company were trading 1.11 per cent down at ₹1,039.25 on the BSE.
Also read: Sun Pharma shares climb 4per cent after Q3 net profit doubles
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.